Skip to main content
Top
Published in: Systematic Reviews 1/2021

Open Access 01-12-2021 | Opioids | Protocol

Substance use and substance use disorder, in relation to COVID-19: protocol for a scoping review

Authors: Navin Kumar, Kamila Janmohamed, Kate Nyhan, Silvia S. Martins, Magdalena Cerda, Deborah Hasin, Jenny Scott, Richard Pates, Lilian Ghandour, Mayyada Wazaify, Kaveh Khoshnood

Published in: Systematic Reviews | Issue 1/2021

Login to get access

Abstract

Background

The COVID-19 pandemic is creating severe issues for healthcare and broad social structures, exposing societal vulnerabilities. Among the populations affected by COVID-19 are people engaged in substance use, such as people who smoke; vape (e-cigarette use); use opioids, cannabis, alcohol, or psychoactive prescription drugs; or have a substance use disorder (SUD). Monitoring substance use and SUD during the pandemic is essential, as people who engage in substance use or present with SUD are at greater risk for COVID-19, and the economic and social changes resulting from the pandemic may aggravate SUD. There have been several reviews focused on COVID-19 in relation to substance use and SUD. Reviews generally did not consider on a large range of substance use variants or SUDs. We plan a scoping review that seeks to fill gaps in our current understanding of substance use and SUD, in the COVID-19 era.

Methods

A scoping review focused on substance use and SUD, in relation to COVID-19, will be conducted. We will search (from January 2020 onwards) Cumulative Index to Nursing and Allied Health Literature, Africa-Wide Information, Web of Science Core Collection, Embase, Global Health, WHO Global Literature on Coronavirus Disease Database, WHO Global Index Medicus, PsycINFO, PubMed, Middle Eastern Central Asian Studies, CINAHL Complete, and Sociological Abstracts. Grey literature will be identified using Disaster Lit, Google Scholar, HSRProj, governmental websites, and clinical trials registries (e.g., ClinicalTrial.​gov, World Health Organization, International Clinical Trials Registry Platform and International Standard Randomized Con-trolled Trial Number registry). Study selection will conform to Joanna Briggs Institute Reviewers’ Manual 2015 Methodology for JBI Scoping Reviews. Only English language, original studies investigating substance use and SUD, in relation to COVID-19 in all populations and settings, will be considered for inclusion. Two reviewers will independently screen all citations, full-text articles, and abstract data. A narrative summary of findings will be conducted. Data analysis will involve quantitative (e.g., frequencies) and qualitative (e.g., content and thematic analysis) methods.

Discussion

Original research is urgently needed to mitigate the risks of COVID-19 on substance use and SUD. The planned scoping review will help to address this gap.

Systematic review registration

Open Science Framework (osf/io/tzgm5).
Appendix
Available only for authorised users
Literature
1.
go back to reference Volkow ND. Collision of the COVID-19 and addiction epidemics. American College of Physicians; 2020. Volkow ND. Collision of the COVID-19 and addiction epidemics. American College of Physicians; 2020.
2.
go back to reference Association AP, et al. Diagnostic and statistical manual of mental disorders (DSM-5QR ). American Psychiatric Pub; 2013. Association AP, et al. Diagnostic and statistical manual of mental disorders (DSM-5QR ). American Psychiatric Pub; 2013.
3.
go back to reference Wj G, Zy N, Hu Y, Wh L, Cq O, Jx H, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020;382(18):1708–20.CrossRef Wj G, Zy N, Hu Y, Wh L, Cq O, Jx H, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020;382(18):1708–20.CrossRef
4.
go back to reference Zhang Jj, Dong X, Cao Yy, Yuan Yd, Yang Yb, Yan Yq, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;. Zhang Jj, Dong X, Cao Yy, Yuan Yd, Yang Yb, Yan Yq, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;.
5.
go back to reference Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). European journal of internal medicine. 2020;. Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). European journal of internal medicine. 2020;.
6.
go back to reference Madison MC, Landers CT, Gu BH, Chang CY, Tung HY, You R, et al. Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. The Journal of clinical investigation. 2019;129(10). Madison MC, Landers CT, Gu BH, Chang CY, Tung HY, You R, et al. Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. The Journal of clinical investigation. 2019;129(10).
7.
go back to reference Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. American College of Physicians; 2020. Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. American College of Physicians; 2020.
8.
go back to reference Abuse S, et al. Federal guidelines for opioid treatment programs. HHS publication no(SMA) PEP15-FEDGUIDEOTP. 2015;. Abuse S, et al. Federal guidelines for opioid treatment programs. HHS publication no(SMA) PEP15-FEDGUIDEOTP. 2015;.
9.
go back to reference Bao Y, Williams AR, Schackman BR. COVID-19 could change the way we respond to the opioid crisis—for the better. Psychiatric Services. 2020;p. appi–ps. Bao Y, Williams AR, Schackman BR. COVID-19 could change the way we respond to the opioid crisis—for the better. Psychiatric Services. 2020;p. appi–ps.
10.
go back to reference Leppla IE, Gross MS. Optimizing Medication Treatment of Opioid Use Disorder During COVID-19 (SARS-CoV-2). Journal of Addiction Medicine. 2020;. Leppla IE, Gross MS. Optimizing Medication Treatment of Opioid Use Disorder During COVID-19 (SARS-CoV-2). Journal of Addiction Medicine. 2020;.
11.
go back to reference Sun Y, Bao Y, Kosten T, Strang J, Shi J, Lu L. Challenges to opioid use disorders during COVID-19. The American Journal on Addictions. 2020;29(3):174.CrossRef Sun Y, Bao Y, Kosten T, Strang J, Shi J, Lu L. Challenges to opioid use disorders during COVID-19. The American Journal on Addictions. 2020;29(3):174.CrossRef
12.
go back to reference Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. bmj. 2017;357. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. bmj. 2017;357.
13.
go back to reference Farhoudian A, Radfar SR, Ardabili HM, Rafei P, Ebrahimy M, Zonoozi AK, et al. A global survey on changes in the supply, price and use of illicit drugs and alcohol, and related complications during the 2020 COVID-19 pandemic. medRxiv. 2020;. Farhoudian A, Radfar SR, Ardabili HM, Rafei P, Ebrahimy M, Zonoozi AK, et al. A global survey on changes in the supply, price and use of illicit drugs and alcohol, and related complications during the 2020 COVID-19 pandemic. medRxiv. 2020;.
14.
go back to reference Cerd́a M, Mauro C, Hamilton A, Levy NS, Santaella-Tenorio J, Hasin D, et al. Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA psychiatry. 2020;77(2):165–71.CrossRef Cerd́a M, Mauro C, Hamilton A, Levy NS, Santaella-Tenorio J, Hasin D, et al. Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA psychiatry. 2020;77(2):165–71.CrossRef
15.
go back to reference Da BL, Im GY, Schiano TD. COVID-19 hangover: a rising tide of alcohol use disorder and alcohol-associated liver disease. Hepatology. 2020;. Da BL, Im GY, Schiano TD. COVID-19 hangover: a rising tide of alcohol use disorder and alcohol-associated liver disease. Hepatology. 2020;.
16.
go back to reference Szabo G, Saha B. Alcohol’s effect on host defense. Alcohol research. 2015;37(2):159.PubMed Szabo G, Saha B. Alcohol’s effect on host defense. Alcohol research. 2015;37(2):159.PubMed
17.
go back to reference Vaillant GE. The natural history of alcoholism revisited. Harvard University Press; 2009. Vaillant GE. The natural history of alcoholism revisited. Harvard University Press; 2009.
18.
go back to reference Clay JM, Parker MO. Alcohol use and misuse during the COVID-19 pandemic: a potential public health crisis? The Lancet Public Health. 2020;5(5):e259.CrossRef Clay JM, Parker MO. Alcohol use and misuse during the COVID-19 pandemic: a potential public health crisis? The Lancet Public Health. 2020;5(5):e259.CrossRef
19.
go back to reference Brondani MA, Alan R, Donnelly L. Stigma of addiction and mental illness in healthcare: the case of patients’ experiences in dental settings. PloS one. 2017;12(5):e0177388.CrossRef Brondani MA, Alan R, Donnelly L. Stigma of addiction and mental illness in healthcare: the case of patients’ experiences in dental settings. PloS one. 2017;12(5):e0177388.CrossRef
20.
go back to reference Vardavas CI, Nikitara K. COVID-19 and smoking: a systematic review of the evidence. Tobacco induced diseases. 2020;18. Vardavas CI, Nikitara K. COVID-19 and smoking: a systematic review of the evidence. Tobacco induced diseases. 2020;18.
21.
go back to reference Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine & Tobacco Research. 2020;. Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine & Tobacco Research. 2020;.
22.
go back to reference Farsalinos K, Barbouni A, Niaura R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Internal and Emergency Medicine. 2020:1–8. Farsalinos K, Barbouni A, Niaura R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Internal and Emergency Medicine. 2020:1–8.
23.
go back to reference Ramalho R. Alcohol consumption and alcohol-related problems during the COVID-19 pandemic: a narrative review. Australasian Psychiatry. 2020;p. 1039856220943024. Ramalho R. Alcohol consumption and alcohol-related problems during the COVID-19 pandemic: a narrative review. Australasian Psychiatry. 2020;p. 1039856220943024.
24.
go back to reference Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID-19 severity: a systematic review and meta-analysis. Journal of Medical Virology. 2020;. Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID-19 severity: a systematic review and meta-analysis. Journal of Medical Virology. 2020;.
25.
go back to reference Mallet J, Dubertret C, Le Strat Y. Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2020;p. 110070. Mallet J, Dubertret C, Le Strat Y. Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2020;p. 110070.
26.
go back to reference Ornell F, Moura HF, Scherer JN, Pechansky F, Kessler F, von Diemen L. The COVID-19 pandemic and its impact on substance use: implications for prevention and treatment. Psychiatry research. 2020;p. 113096. Ornell F, Moura HF, Scherer JN, Pechansky F, Kessler F, von Diemen L. The COVID-19 pandemic and its impact on substance use: implications for prevention and treatment. Psychiatry research. 2020;p. 113096.
27.
go back to reference Arksey H, O’Malley L. Scoping studies: towards a methodological framework. International journal of social research methodology. 2005;8(1):19–32.CrossRef Arksey H, O’Malley L. Scoping studies: towards a methodological framework. International journal of social research methodology. 2005;8(1):19–32.CrossRef
28.
go back to reference Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015;4(1):1.CrossRef Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015;4(1):1.CrossRef
29.
go back to reference Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Annals of internal medicine. 2018;169(7):467–73.CrossRef Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Annals of internal medicine. 2018;169(7):467–73.CrossRef
30.
go back to reference Joanna Briggs Institute and others. Joanna Briggs institute reviewers’ manual 2015—methodology for JBI scoping reviews. Adelaide; 2015;. Joanna Briggs Institute and others. Joanna Briggs institute reviewers’ manual 2015—methodology for JBI scoping reviews. Adelaide; 2015;.
31.
go back to reference Lefebvre C, Duffy S. Peer reviewing search strategies. HTAi vortal. 2018;. Lefebvre C, Duffy S. Peer reviewing search strategies. HTAi vortal. 2018;.
32.
go back to reference Clarivate Analytics. Endnote X8 for windows. Philadelphia, PA: Clarivate Analytics. 2017;. Clarivate Analytics. Endnote X8 for windows. Philadelphia, PA: Clarivate Analytics. 2017;.
33.
go back to reference Nussbaumer-Streit B, Klerings I, Dobrescu A, Persad E, Stevens A, Garritty C, et al. Excluding non-English publications from evidence-syntheses did not change conclusions: a meta-epidemiological study. Journal of Clinical Epidemiology. 2020;118:42–54.CrossRef Nussbaumer-Streit B, Klerings I, Dobrescu A, Persad E, Stevens A, Garritty C, et al. Excluding non-English publications from evidence-syntheses did not change conclusions: a meta-epidemiological study. Journal of Clinical Epidemiology. 2020;118:42–54.CrossRef
34.
go back to reference Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. International journal of technology assessment in health care. 2012;28(2):138.CrossRef Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. International journal of technology assessment in health care. 2012;28(2):138.CrossRef
35.
go back to reference Scherer RW, Saldanha IJ. How should systematic reviewers handle conference abstracts? A view from the trenches. Systematic reviews. 2019;8(1):264.CrossRef Scherer RW, Saldanha IJ. How should systematic reviewers handle conference abstracts? A view from the trenches. Systematic reviews. 2019;8(1):264.CrossRef
36.
go back to reference Turner RM, Bird SM, Higgins JP. The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PloS one. 2013;8(3):e59202.CrossRef Turner RM, Bird SM, Higgins JP. The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PloS one. 2013;8(3):e59202.CrossRef
37.
go back to reference VH Innovation. Covidence systematic review software. Melbourne, Australia. 2017;. VH Innovation. Covidence systematic review software. Melbourne, Australia. 2017;.
38.
go back to reference Silagy CA, Middleton P, Hopewell S. Publishing protocols of systematic reviews: comparing what was done to what was planned. Jama. 2002;287(21):2831–4.CrossRef Silagy CA, Middleton P, Hopewell S. Publishing protocols of systematic reviews: comparing what was done to what was planned. Jama. 2002;287(21):2831–4.CrossRef
39.
go back to reference Paul E, Brown GW, Ridde V. COVID-19: time for paradigm shift in the nexus between local, national and global health. BMJ global health. 2020;5(4):e002622.CrossRef Paul E, Brown GW, Ridde V. COVID-19: time for paradigm shift in the nexus between local, national and global health. BMJ global health. 2020;5(4):e002622.CrossRef
40.
go back to reference Miake-Lye IM, Hempel S, Shanman R, Shekelle PG. What is an evidence map? A systematic review of published evidence maps and their definitions, methods, and products. Systematic reviews. 2016;5(1):28.CrossRef Miake-Lye IM, Hempel S, Shanman R, Shekelle PG. What is an evidence map? A systematic review of published evidence maps and their definitions, methods, and products. Systematic reviews. 2016;5(1):28.CrossRef
41.
go back to reference Bostrom AM, Slaughter SE, Chojecki D, Estabrooks CA. What do we know about knowledge translation in the care of older adults? A scoping review. Journal of the American Medical Directors Association. 2012;13(3):210–9.CrossRef Bostrom AM, Slaughter SE, Chojecki D, Estabrooks CA. What do we know about knowledge translation in the care of older adults? A scoping review. Journal of the American Medical Directors Association. 2012;13(3):210–9.CrossRef
Metadata
Title
Substance use and substance use disorder, in relation to COVID-19: protocol for a scoping review
Authors
Navin Kumar
Kamila Janmohamed
Kate Nyhan
Silvia S. Martins
Magdalena Cerda
Deborah Hasin
Jenny Scott
Richard Pates
Lilian Ghandour
Mayyada Wazaify
Kaveh Khoshnood
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2021
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/s13643-021-01605-9

Other articles of this Issue 1/2021

Systematic Reviews 1/2021 Go to the issue